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Background. HIV specific T cells are putatively anergic in vivo. IL-2, a member of a class of cytokines that binds to receptors
containing the common gamma chain (cc) has been shown to reverse anergy. We examined the role of cc cytokines in
reversing HIV specific T cell anergy. Methods. PBMC from untreated HIV-infected individuals were briefly exposed to a panel
of cc cytokines, and frequencies of gag specific T cells were enumerated by intracellular IFN-c flow cytometry. Results. Of the
cc cytokines, brief exposure to IL-2, IL-15, or combined IL-15/IL-7 significantly enhanced (range 2–7 fold) the CD4
+ and CD8
+ T
cell IFN-c responses to HIV gag, with IL-15 giving the greatest enhancement. The effects of cytokines were not due to enhanced
proliferation of pre-existing antigen specific cells, but were due to a combination of enhanced cytokine production from
antigen specific T cells plus activation of non-epitope specific T cells. Conclusions. These observations support the notion that
a significant number of HIV specific T cells are circulating in an anergic state. IL-2, IL-7 and particularly IL-15 as an immune
modulator to reverse HIV-1 specific T cell anergy should be investigated, with the caveat that non-specific activation of T cells
may also be induced.
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INTRODUCTION
Although a potent CD4
+ and CD8
+ T cell immune response has
been shown to control most virus infections, Human Immunode-
ficiency Virus (HIV) replication persists in the majority of infected
individuals despite the presence of a detectable T cell immune
response[1–5]. Analysis of T cell immune responses in HIV-
infected individuals have revealed a number of apparent
functional defects whose severity correlate closely with the degree
of viral replication in the plasma. When compared to T cells of
other viral specificities, HIV-specific T cells have been shown to
have defects in proliferative capacity, cytokine production and
effector function [6–14]. More specifically, using MHC-class I
peptide-tetramer technology, HIV and SIV specific CD8
+ T cells
have been shown to be impaired in their ability to produce
interferon-gamma (IFN-c) in which less than 25% of tetramer-
staining cells are able to produce cytokine in response to their
cognate antigen [10,11,15,16]. Similar defects have also been
proposed in HIV-specific CD4
+ T cells, in which, viral replication
is associated with a defect in IL-2 production [7,9,17]. Since
a direct comparison of HIV-specific CD4
+ T cells by tetramer
analysis and cytokine production is yet to be reported due to the
difficulties in producing stable peptide-MHC class II tetramers, it
is unknown what proportion of HIV-specific CD4
+ T cells are
defective in IL-2 or IFN-c production in acute and chronic
infection [18]. A number of mechanisms for this anergic or
‘stunned’ state of antigen specific T cells in HIV infection have
been proposed, which include excessive activation from high
antigen loads [7,19], direct effects of gp120[20], or altered peptide
ligands encoded due to viral mutants [21].
The common-gamma (cc) chain cytokines have been shown to
be important growth factors for T cells [22] and of which IL-2, has
been shown to reverse anergy in vitro[23,24]. The common
cytokine receptor gamma chain is essential for the function of at
least six cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-
21. IL-2 is the most well characterized of these, and has been used
in clinical trials to enhance CD4 counts in HIV infected
individuals [25–28], however, its direct effect on HIV-specific T
cells has not been well characterized. Although IL-2 is a T-cell
growth factor, it also enhances apoptosis of mature T cells and
induces tolerance by expanding CD25
+ regulatory CD4
+ T cells
[29,30]. IL-7 is important in T cell homeostasis by enhancing the
survival of central memory T cells. IL-15 has been demonstrated
to ensure the survival and proliferation of memory CD4
+ and
CD8
+ T cells and NK cells. IL-4 primarily mediates the
development of humoral immunity by promoting TH2 CD4
+ T
cells and B cell proliferation[22]. Thus, although members of the
common cc cytokine family show considerable overlap, many
differences in their functional characteristics are also found. In
addition, it is unknown whether IL-7, IL-4 or IL-15 are capable of
reversing anergy via signaling through the cc chain.
In the current study, we asked whether brief treatment of ex vivo
HIV-specific T cells with various members of the cc cytokine
family could reverse their anergic state. We sought to determine
the relative effectiveness of these cytokines in reversing anergy as
well as possible mechanisms as to how these cytokines work on
antigen specific T cells.
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Study participants
17 treatment naive HIV infected individuals were recruited for this
study (see Table 1). Eight individuals were recently infected by
HIV within 6 months of study (diagnosed by recent seroreactivity).
Nine individuals with chronic HIV infection with disease
progression were studied. This was defined as documented HIV
infection .1 year, with evident CD4
+ T cell decline of .50 CD4
cells/ mm
3 and a viral load .10,000 copies/ml. All investigational
protocols were approved by the University of Toronto and St.
Michael’s hospital Institutional Review Boards.
Source of antigens
Forty-nine overlapping 20mer peptides spanning the gag region of
HIV-IIIB (amino acids 1–500), overlapping by 10 amino acids,
were obtained from the NIH AIDS Research Reagent program
(catalog # 3992), dissolved in DMSO and used as a pool with each
peptide at a final concentration of 1.0 mg/ml. DMSO in
appropriate dilutions was used as a negative control.
Cell preparation
Peripheral blood mononuclear cells (PBMC) were Ficoll-separated
(LSM, Organon Teknika, Durham, NC) from freshly obtained
blood samples and washed in PBS (BioWhittaker, Walkersville,
MD) and cultured in RPMI-10%HAB serum (BioWhittaker,
Walkersville, MD). Cells were cultured overnight (16 hours) in the
following conditions, a) medium alone, b) IL-2 (25U/ml), c) IL-15
(25 ng/ml), d) IL-7 (25 ng/ml), e) IL-15+IL-7 (each at 25 ng/ml),
and f) IL-4 (25ng/ml). IL-2 was obtained from the NIH AIDS
Reagent Program whereas IL-15, Il-7 and IL-4 were obtained
from R&D Systems (Minneapolis, MN). The following day, cells
from each condition were washed of cytokines with PBS62 and
then resuspended in RPMI-10%HAB medium and stimulated for
12 hours by an HIV gag peptide pool (see above) or control antigen
(DMSO) in the presence of monensin and 1 mg/ml of anti-CD49d
and CD-28 antibodies for co-stimulation (BD Biosciences, San
Diego, CA). Cells were then harvested and assessed for in-
tracellular cytokines.
Flow cytometry and intracellular cytokine
determination
The procedure for intracellular staining of cytokines in PBMCs was
performed using the Cytofix/cytoperm Plus kit according to the
manufacturer’s instructions (Cat# 554715, BD Biosciences, San
Diego, CA). Cells were washed, fixed and permeabilized in FACS
permeabilization buffer and were stained by a panel of conjugated
antibodies (fluorescein isothiocyanate (FITC), phycoerythrin (PE),
peridinin chlorophyll protein (PerCP) and allophycocyanin (APC)
including antibodies to human CD4, CD8, CD69 (Pharmingen),
and IFN-c and respective isotype controls. Cells were then washed
and resuspended in 1% paraformaldehyde/PBS and then analyzed
the following day on a FACSCalibur (BD Biosciences, San Diego,
CA). All antibodies were obtained from BD Biosciences. In selected
experiments, PBMC from HLA-A *0201 individuals who had CD8
+
T cell responses to the SLYNTVATL epitope of HIV gag were also
stained with the MHC-I tetramer to this peptide (iTag, Beckman-
Coulter, Fullerton, CA). In the latter experiments cells were washed
three times with PBS to ensure removal of peptide prior to tetramer
staining. Data were acquired by Cell Quest software (BD
Biosciences, San Diego, CA) and analyzed using FloJo (Treestar
Inc., San Carlos, CA). From 100,000 to 200,000 events in the
lymphocyte gate were acquired/sample.
Proliferation assays
To more specifically determine the effect of cytokines on the
proliferative activity of antigen specific cells in our assays, stable
incorporation of the intracellular fluorecent dye 5-(and–6)-
carboxyfluorescein diacetate succinimidyl ester (CFSE) was
employed. PBMCs were suspended in PBS containing 5% FBS
and were stained at room temperature for 5 min with 5 mM
CFSE. Staining was terminated by adding PBS containing 5%
fetal bovine serum (FBS) and subsequent washing with PBS. Cells
were then treated similarly as above for antigen specific assays.
Proliferation was assessed by measuring dilution of CFSE staining
on antigen specific cells that were co-stained with antibodies to
CD4, CD8 and IFN-c.
Statistical analysis
Data were compared using the Wilcoxon signed rank test for
paired samples (two-tailed).
RESULTS
Effect of brief exposure to cc cytokines on HIV
specific T cell responses
Since gag is the most conserved protein of HIV and elicits the most
frequent T cell responses in HIV infected individuals, we elected to
study the effects of cc cytokines on the T cell response to HIV gag
in a cohort of untreated HIV infected individuals with recent
seroconversion or chronic progressive disease (see Table 1).
Individuals with recent seroconversion were studied because of
the high levels of immune activation and viremia associated with
this stage of infection [31–34]. We asked whether short term
overnight treatment of HIV- gag specific T cells could reverse any
defect in IFN-c production that may be occurring in vivo. Freshly
obtained ex vivo PBMC were treated overnight in plain medium or
with the following cytokines or combination, thereof: IL-2, IL-15,
Table 1. Profiles of HIV-1 Infected Participants
......................................................................
Patient Clinical Diagnosis CD4 Count/mm3 Viral Load(copies/ml)
1 Recent Sero 660 440,000
2 Recent Sero 810 224,000
3 Recent Sero 180 28,650
4 Recent Sero 300 150,660
5 Recent Sero 440 8,571
6 Recent Sero 550 250,000
7 Recent Sero 600 118,778
8 Recent Sero 363 171,830
9 Chronic 132 22,415
10 Chronic 410 40,021
11 Chronic 539 175,000
12 Chronic 170 47,000
13 Chronic 200 75,000
14 Chronic 80 50,964
15 Chronic 520 10,719
16 Chronic 340 200,000
17 Chronic 200 105,497
Recent Sero-Recently acquired HIV-1 infection within 6 months
Chronic HIV-HIV-1-infected .1 year with CD4 decline
doi:10.1371/journal.pone.0000300.t001
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PLoS ONE | www.plosone.org 2 March 2007 | Issue 3 | e300IL-4 or IL-7+IL-15. The latter combination of IL-7+IL-15 was
previously shown to have a synergistic effect on inducing the
proliferation of memory T cells [22]. The following day, PBMC
were washed extensively to remove residual cytokines, exposed to
HIV gag or control antigen, and then assessed for their ability to
produce IFN-c as measured by intracellular flow cytometry. An
example of a representative experiment from Participant #11,
a chronic progressor, is shown in Figure 1a and b depicting both
control and antigen stimulated conditions in CD4
+ (Fig. 1a) and
CD8
+ T (Fig. 1b) cells. The frequency of HIV gag specific T cells
was calculated by measuring IFN-c/CD69 expressing cells
observed in HIV gag containing conditions and subtracting from
DMSO (control antigen) containing conditions, similar to as
previously described [35]. In this individual, when PBMC were
cultured in plain medium the measured frequency of gag specific
IFN-c producing CD4
+ T was .082%. However, if the PBMCs
were briefly exposed to IL-2, the measured frequency increased to
0.326%, if they were exposed to IL-15, the frequency was 0.45%,
to both IL-15/IL7 it was 0.66%, whereas, if cells were briefly
exposed to IL-4, we only detected a frequency of 0.047%.
Similarly, for CD8
+ T cells, we detected a 0.02% frequency of gag
specific IFN-c producing cells if PBMC were briefly cultured in
plain medium, whereas the frequencies increased to 0.46%, 0.6%,
0.6% or 0.06% if they were briefly cultured in the presence of IL-
2, IL-15, IL-15/IL-7, or IL-4, respectively. Data from participant
#5, a recent seroconverter is also depicted in Figure 2. When
combining data from all 17 individuals (Table 2), the frequency of
gag specific CD4
+ T cells detected after brief treatment with
medium, IL-2, IL-15, IL-15/7 or IL-4 were 0.08%, 0.23%
(p,0.005 vs medium), 0.50% (p,0.001 vs medium), 0.53%
(p,0.005 vs medium) and 0.08% (p=n.s vs medium) respectively,
and for gag specific CD8
+ T cells; 0.52%, 1.0% (p,0.001 vs
medium), 1.58% (p,0.001 vs medium), 2.0% (p,0.001 vs
medium) and 0.52% (p=n.s vs medium), respectively. In addition,
the frequency of gag specific CD4
+ and CD8
+ T cells was
significantly greater with IL-15 or IL-15/7 compared to IL-2
(p,.05, and p,.005 respectively). Although, treating CD4
+ and
CD8
+ T cells with IL-15/7 combined tended to give higher
responses compared to IL-15 alone, the differences failed to reach
statistical significance. Culturing cells in the presence of IL-4 failed
to enhance gag specific T cell responses. Thus, when ex vivo PBMC
are cultured overnight in the presence of the cc cytokines, IL-2, IL-
15, or combined IL-15/IL-7 one can enhance the CD4
+ and
CD8
+ T cell IFN-c responses to HIV gag.
Figure 1. Effect of cc cytokines on HIV specific T cell responses in a chronic progressor. Fresh ex vivo PBMC from an HIV infected individual with chronic
progression (Pt# 11) were incubated overnight in the following culture conditions: medium, IL-2 (20U/ml), IL-15 (20 ng/ml), IL-15+IL-7 (20 ng/ml
each), or IL-4 (20 ng/ml). The following day, cells were washed twice, resuspended in plain medium and then stimulated with control antigen (DMSO)
or a gag peptide pool in the presence of Monensin, and then stained for intracellular cytokines. Shown are dot plots of gag or control antigen
stimulated samples from PBMC in respective culture conditions, for CD4
+ T cells (a) or CD8
+ T cells (b). The upper right numbers in the right hand
panels indicate the % of HIV gag specific IFN-c producing CD4
+ or CD8
+ T cells after subtraction from DMSO controls (left panel).
doi:10.1371/journal.pone.0000300.g001
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PLoS ONE | www.plosone.org 3 March 2007 | Issue 3 | e300Effect of brief exposure of cc cytokines on
proliferation of HIV specific cells
We saw a dramatic enhancement (range 2–7 fold) in the frequency
of IFN-c producing T cell responses after exposure to IL-2 or IL-
15. One possibility is that exposure to these cytokines allowed
proliferation of antigen specific cells overnight in vitro prior to their
detection by intracellular cytokine staining. In order to address
this, in selected participants, PBMC were stained with CFSE prior
to performing experiments in order to assess proliferation of
antigen specific cells via the effect of proliferation on diluting the
CFSE stain. A representative experiment comparing medium and
IL-15 conditions in Participant #7 is shown in Figure 3. We find
that IFN-c producing T cells do not dilute CFSE in the presence of
IL-15 indicating that the enhanced frequency of IFN-c producing
cells is not due to proliferation overnight.
Antigen specificity of enhanced responses due to cc
cytokines
An alternative possibility of the enhanced responses observed with
IL-2 and IL-15 pretreatment may be related to activation of cells
not specific for the antigen. In order to address this, we examined
the effect of overnight IL-2 and IL-15 treatment on CD8
+ T cells
specific for the HLA-A2*0201 restricted epitope of HIV gag,
SLYNTAVTL, using tetramer co-staining experiments. PBMC
from three HLA-A2*0201 positive individuals with chronic
progressive HIV infection, who previously showed detectable
IFN-c responses to the this epitope, were treated overnight with
medium, IL-2, or IL-15, and then were stimulated for 6 hours
with the SLYNTVATL peptide, and assessed for intracellular
IFN-c production by flow cytometry. A representative experiment
is depicted in Figure 4a, with summary data from all three
individuals shown in Figures 4b-d. As demonstrated with the
CFSE experiments, brief cytokine treatment did not enhance the
proliferation of antigen specific T cells since the numbers of
tetramer staining cells were similar with all three conditions
(Figure 4a and d). SLYNTAVTL specific CD8
+ T cells from these
three individuals showed severe anergy, as ,10% of tetramer
staining cells could produce IFN-c upon stimulation. Brief
treatment with IL-2 or IL-15 was able to partially reverse this
anergy, with IL-15 being more effective than IL-2 at increasing the
proportion of tetramer staining cells to produce IFN-c (Figure 4a
and b). The detection of increased IFN-c expressing cells after
SLYNTVATL stimulation was however, also associated with an
increase frequency of tetramer negative but IFN-c positive cells,
which was most significantly seen in the IL-15 containing
condition, indicating that a portion of the IL-15 effect is not
SLYNTVATL specific (Figure 4a and c). Since a portion of the
enhancing effect of IL-2 and in particular, IL-15 was due to cells
that were not antigen specific, we looked at the expression of the
activation marker, CD69, in cells that were pretreated with cc
cytokines in the absence of HIV antigen. As can be observed in
Figure 1a and b, baseline CD69 expression is enhanced in control
antigen conditions in cells pretreated with IL-2 or IL-15. For all
samples, the baseline levels of CD69 expression on CD4+ T cells
with medium, IL-2, IL-15, IL-15/7, and IL-4 were 2.3%, 5.0%,
7.5%, 5.9% and 2.9% respectively, (p,.05 for medium vs IL-2,
IL-15 and IL-15/7, data not shown); and on CD8+ T cells with
medium, IL-2, IL-15, IL-15/7, and IL-4 were 4.1%, 7.8%, 17.7%,
15.1% and 4.7%, respectively, (p,.05 for medium vs IL-2, IL-15
and IL-15/7, data not shown). Thus, brief pretreatment of T cells
with cc cytokines IL-2, and IL-15 but not IL-4 enhances their
activation state, which is more pronounced with IL-15.
Figure 2. Effect of cc cytokines on HIV specific T cell responses in an acute
seroconverter. Fresh ex vivo PBMC from an HIV infected individual with
acute HIV infection (Pt# 5) were incubated overnight similarly to as in
Figure 1. Shown are dot plots of HIV gag antigen stimulated samples for
CD4
+ T cells and CD8
+ T cells (DMSO control conditions not shown). The
upper right numbers indicate the % of HIV gag specific IFN-c producing
CD4
+ (left panel) or CD8
+ T cells (right panel) after subtraction from
DMSO controls (not shown).
doi:10.1371/journal.pone.0000300.g002
Table 2. Summary data from 17 HIV-1 infected individuals with chronic progressive or acute HIV-1 infection.
..................................................................................................................................................
Condition (overnight incubation) medium IL-2 IL-15 IL-15+IL-7 IL-4
Mean frequency of gag specific CD4 (% of CD4+ T cells) 0.08 0.23# 0.50* 0.53# 0.08ˆ
Mean frequency of gag specific CD8(% of CD8+ T cells) 0.52 1.00* 1.58* 2.00* 0.52ˆ
*p,0.001 compared to medium; #p,0.005 compared to medium;ˆp=not significant compared to medium
doi:10.1371/journal.pone.0000300.t002
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In the current study, we show that brief treatment of ex vivo
PBMCs obtained from untreated HIV infected individuals, with
the cc cytokines IL-2, IL-15 or IL-15 plus IL-7 can to varying
extents, enhance the ability of HIV-specific CD4
+ and CD8
+ T
cells to produce IFN-c. Our findings support those of others in
which the addition of IL-15 could enhance IFN-c ELISpot
responses to CMV, or PPD in healthy donors[36], to HIV in
treated HIV-infected children[37], and to SIV in SIV infected
macaques[38]. These observations support the notion that
a significant number of HIV-1 specific CD4
+ and CD8
+ T cells
are circulating in an anergic or unresponsive state. This was
confirmed by finding that cc cytokines increase the proportion of
HIV specific CD8
+ T cells directed against the SLYNTVATL
epitope (p17) to produce IFN-c, and that this effect occurred
independantly of any effect on proliferation of these cells. IL-15 or
the combination of IL-15 plus IL-7 was the most potent at
reversing anergy, whereas, IL-4 had no effect. Although IL-15
could enhance the ability of p17-specific CD8
+ T cells to produce
IFN-c, the majority of tetramer positive cells still could not secrete
IFN-c in response to peptide stimulation, indicating the intense
anergic state of these cells in the individuals studied. It is possible
that more prolonged culture of cells (e.g., 1–2 weeks) in the
presence of cytokines may have more extensively reversed this
defect. We used a short (12 hour) exposure in our study in order to
avoid any effect of these cytokines on proliferation of antigen
specific cells in vitro, and because we were interested in determining
whether ex vivo antigen specific cells were indeed anergic.
Figure 3. Effect of cc cytokine treatment on proliferation of HIV specific T cells. Ex vivo PBMC obtained from Participant #7 were labeled with CFSE and
then incubated in medium or IL-15 as described above. PBMC were then washed and then exposed to HIV gag or control antigen (not shown) and
tested for intracellular IFN-c. Shown are dot plots of antigen stimulated conditions for CD4
+ and CD8
+ T cells. The increased numbers of IFN-c
producing T cells after IL-15 exposure is not associated with any dilution of CFSE staining. Numbers represent % of HIV gag specific IFN-c producing
cells. Shown, are representative data of one of three experiments.
doi:10.1371/journal.pone.0000300.g003
Cytokines, HIV T Cell Anergy
PLoS ONE | www.plosone.org 5 March 2007 | Issue 3 | e300The lack of significant effects with IL-4 suggests that signaling
through the common cc alone is not sufficient to reverse anergy
but that signaling through additional cytokine specific chains like
IL-2Rb and IL-15b may also be necessary. All of the cc cytokines,
activate the jak1 and jak3 kinases upon binding to their specific
and the common gamma chains, respectively. However, down-
stream to jak activation, IL-2, IL-15 and IL-7 signaling then
specifically phosphorylate stat 3 and stat 5, whereas, IL-4 signaling
phosphorylates stat 6. Thus, it appears likely that stat 3 and stat 5
activation are responsible in part for the effects observed. The
mechanisms as to how IL-2 and IL-15 enhance the effect of
signaling through the TCR are beginning to emerge. Recently Liu
et al.[39] showed by genetic profiling microarray analysis, that
73% of genes upregulated by IL-15 on memory T cells overlap
with genes upregulated by TCR signals on the same cells. These
findings suggest that signals induced through the TCR could be
amplified via IL-15 as similar genes are being upregulated, with
the resulting effect being decreasing the threshold for T cell
activation through the TCR after exposure to antigen. This is
consistent with what we observed in our cohort, as, IL-2, IL-15
and IL-15/7 enhanced the baseline activation state of T cells by
enhancing CD69 expression, a marker of activation through the
TCR. Thus, the beneficial effect of IL-2 or IL-15 appeared to
occur at the expense of enhanced background activation of T cells.
In our tetramer analysis, the effects of enhanced activation was
associated with enhanced IFN-c production from cells which did
not appear to be specific to the peptide stimulus. It is unclear
whether this represents activation of cells with TCRs that cross-
react to the peptide, and thus are activated because the threshold
of activation was lowered, or reflect completely non-specific
activation.
The cc cytokines, including IL-2, IL-15 and IL-7 are currently
receiving consideration for treatment in HIV infection as systemic
therapies. Our data suggests that all should potentially be useful in
enhancing the functional capacity of HIV specific T cells in vivo,
with IL-15 or combined IL-15 plus IL-7 showing the most potent
effects. Clinical use of these cytokines however may also be
associated with an enhanced activation state of T cells, particularly
with IL-15, which may have both positive effects or negative
consequences. A positive effect would be the recruitment of
potentially cross reactive T cells that could deal with virus variants
that escape from the immunodominant response. The negative
effect would be that enhanced immune activation would facilitate
further HIV viral replication.
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